Presentation is loading. Please wait.

Presentation is loading. Please wait.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Published byAustin Atkins Modified over 8 years ago

Similar presentations

Presentation on theme: "Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal."— Presentation transcript:

1 Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal Women with Hormone Receptor Positive Early Breast Cancer: Joint Analysis of IBCSG TEXT and SOFT Presented By Olivia Pagani at 2014 ASCO Annual Meeting

2 TEXT and SOFT Presented By Olivia Pagani at 2014 ASCO Annual Meeting

3 TEXT and SOFT Worldwide Collaborative Presented By Olivia Pagani at 2014 ASCO Annual Meeting

4 Premenopausal Endocrine Therapy Presented By Olivia Pagani at 2014 ASCO Annual Meeting

5 TEXT - SOFT Trials Aromatase Inhibitor Question Presented By Olivia Pagani at 2014 ASCO Annual Meeting

6 TEXT and SOFT Designs Presented By Olivia Pagani at 2014 ASCO Annual Meeting

7 Eligibility Presented By Olivia Pagani at 2014 ASCO Annual Meeting

8 Treatments Presented By Olivia Pagani at 2014 ASCO Annual Meeting

9 Study Procedures Presented By Olivia Pagani at 2014 ASCO Annual Meeting

10 Endpoints Presented By Olivia Pagani at 2014 ASCO Annual Meeting

11 Statistical Considerations Presented By Olivia Pagani at 2014 ASCO Annual Meeting

12 Characteristics Presented By Olivia Pagani at 2014 ASCO Annual Meeting

13 Exemestane+OFS Improved DFS Presented By Olivia Pagani at 2014 ASCO Annual Meeting

14 Sites of First Failure Presented By Olivia Pagani at 2014 ASCO Annual Meeting

15 Exemestane+OFS Reduced Recurrence Presented By Olivia Pagani at 2014 ASCO Annual Meeting

16 Women Who Did Not Receive Chemotherapy Presented By Olivia Pagani at 2014 ASCO Annual Meeting

17 Women Who Received Chemotherapy Presented By Olivia Pagani at 2014 ASCO Annual Meeting

18 Selected Adverse Events Presented By Olivia Pagani at 2014 ASCO Annual Meeting

19 Adverse Events and QOL Presented By Olivia Pagani at 2014 ASCO Annual Meeting

20 Conclusions Presented By Olivia Pagani at 2014 ASCO Annual Meeting

21 More from TEXT and SOFT Presented By Olivia Pagani at 2014 ASCO Annual Meeting

22 Slide 22 Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Download ppt "Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal."

Similar presentations

Neoadjuvant Hormone Treatment of Breast Cancer H.S.A. Oldenburg E.J.Th. Rutgers J.M. Dixon symposium 29 juni 2005.

Neoadjuvant Hormone Treatment of Breast Cancer H.S.A. Oldenburg E.J.Th. Rutgers J.M. Dixon symposium 29 juni 2005.
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Breast Cancer Systemic Therapy for Early Stage Disease

Breast Cancer Systemic Therapy for Early Stage Disease
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent.

Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent.
Cancer Clinical Trials:

Cancer Clinical Trials:
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,

Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
Cancer Center Trials at St. Barnabas Medical Center.

Cancer Center Trials at St. Barnabas Medical Center.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:

Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:
These slides were released by the speaker for internal use by Novartis.

These slides were released by the speaker for internal use by Novartis.
Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.

Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.
Day 2 Welcome Back ! 8.30 BIG 1-98 Issues 8.45 BIG 1-98 Syndicate 10.00 The Case for Switching ITA & ARNO/ABCSG 10.30 The Switch Call Video 11.00 Statistics.

Day 2 Welcome Back ! 8.30 BIG 1-98 Issues 8.45 BIG 1-98 Syndicate The Case for Switching ITA & ARNO/ABCSG The Switch Call Video Statistics.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.

The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Www.OncologyEducation.ca BIG 1-98/IBCSG 18-98 Henning Mouridsen for the BIG 1-98 Collaborative Group Authors: Sunil Verma Date posted: December 22, 2008.

BIG 1-98/IBCSG Henning Mouridsen for the BIG 1-98 Collaborative Group Authors: Sunil Verma Date posted: December 22, 2008.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.

Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,

Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Similar presentations

Ads by Google